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Background: It is unknown whether serial pulmonary function tests are necessary for the correct diagnosis of
chronic obstructive pulmonary disease (COPD) in patients with stable non-congested chronic heart failure (CHF).
The aim of this study was to determine the prevalence of COPD in outpatients with stable CHF without pulmonary
congestion using initial as well as confirmatory spirometry three months after treatment for COPD.
Methods: Spirometry was performed in 187 outpatients with stable CHF without pulmonary congestion on chest
radiograph who had a left ventricular ejection fraction < 40% (mean age 69 ± 10 years, 78% men). COPD was
defined according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. The diagnosis of COPD
was confirmed three months after treatment with tiotropium in newly diagnosed COPD patients.
Results: Using a three month follow-up spirometry to confirm initial diagnosis of de novo COPD did not change
COPD prevalence significantly: 32.6% initially versus 32.1% after three months of follow-up. Only 1 of 25 (4%)
patients with newly diagnosed COPD was not reproducibly obstructed at follow-up. COPD was greatly under- (19%)
and overdiagnosed (32%).
Conclusions: Spirometry should be used under stable and euvolemic conditions to decrease the burden of
undiagnosed or overdiagnosed COPD in patients with CHF. Under these conditions, a confirmatory spirometry is
unnecessary, as it does not change a newly established diagnosis of COPD in the vast majority of patients with CHF.
Trial registration: ClinicalTrials.gov Identifier NCT01429376.
Keywords: Chronic obstructive pulmonary disease; Chronic heart failure; Prevalence; Serial pulmonary function tests;
Underdiagnosis; OverdiagnosisBackground
Heart failure (HF) is a common clinical condition with
high mortality and morbidity rates [1]. Chronic obstruct-
ive pulmonary disease (COPD) frequently coexists with
HF, leading to poor prognosis as well as diagnostic and
therapeutic challenges [2-17]. Estimates of COPD preva-
lence in patients with HF vary substantially between 9%
and 52% in earlier reports that relied on clinical data,
disease codes, or self-reported COPD for establishing the
diagnosis [2]. Spirometry is considered to be the gold stand-
ard for the diagnosis of COPD [18], but is unfortunately* Correspondence: aminasian@rijnstate.nl
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in any medium, provided the original work is pstill underutilised [19]. Studies that used spirometry have
also reported varying prevalence rates of COPD (9 - 44%)
depending on study design, population, and diagnostic
criteria [14-17,20-23]. Airway obstruction is a dynamic
phenomenon in HF, as it may be present in congestive
HF and may disappear with treatment of HF [14].
Therefore, a careful timing and interpretation of pul-
monary function tests (PFTs) is required to avoid mis-
diagnosis and inappropriate treatment [2]. Ideally, serial
PFTs should be used under stable conditions when clin-
ically euvolemic to establish a valid diagnosis of COPD
by confirming persistent airway obstruction. However,
data on the need of serial pulmonary function measure-
ments are scarce and even lacking in patients with
stable chronic HF (CHF). It is therefore unknown
whether a confirmatory spirometry is necessary for thes an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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congested CHF.
The present study determined the prevalence of
COPD in outpatients with stable CHF without pulmon-
ary congestion using initial as well as confirmatory spir-
ometry three months after treatment with tiotropium in
patients with newly diagnosed COPD.
Methods
Study design and participants
All patients attending two outpatient cardiology depart-
ments of a large general hospital in The Netherlands were
screened for inclusion in this prospective study between
October 2009 and December 2010. In addition, existing
patient lists were used to ensure that the majority of HF
population had been examined for eligibility. Inclusion cri-
teria were CHF [1] with left ventricular ejection fraction
(LVEF) < 40%, New York Heart Association (NYHA) class
I-IV, and age of ≥ 18 years. CHF was defined according to
European Society of Cardiology guidelines [1]. Echocar-
diography was performed in patients without a recent
(≤6 months) echocardiography to confirm persisting left
ventricular systolic dysfunction (LVSD). Patients were clas-
sified as having stable HF in the absence of hospitalization
due to progression of HF within 3 months, change in di-
uretics within 1 month, 3% or more weight gain within
3 days, and more than 50% increase of N-terminal pro-B
natriuretic peptide (NT-pro-BNP) within 1 month when
the baseline NT-pro-BNP was 100 pmol/L or higher or
more than 100 pmol/L increase of NT-pro-BNP within
1 month when baseline NT-pro-BNP was below 100
pmol/L [24]. Pulmonary congestion was evaluated on
standard posterior-anterior and lateral chest radio-
graphs for the presence or absence of alveolar oedema,
pleural effusion, Kerley-B lines, and/or the redistribu-
tion of pulmonary blood flow by independent radiolo-
gists who qualitatively assessed the chest radiographs
with an overall clinical impression. We excluded pa-
tients who were not able to cooperate or undergo spir-
ometry or who had asthma according to their medical
chart. Other exclusion criteria were malignancy with a
poor prognosis (survival < 6 months) and participation
in another cardiology study. Patients who had been
hospitalized in the pulmonary department in the past
six weeks were included six weeks after discharge to
ensure that their pulmonary function was stable at the
time of spirometry testing.
Measurements and data collection
At baseline, a first blood sample was taken for the meas-
urement of NT-pro-BNP according to the standard
methods used at the hospital laboratory. One month
later, the participants visited the hospital for an interview
with the investigator and several examinations, includingheight and weight measurement, spirometry, and a chest
radiograph. In addition, a second blood sample (NT-
pro-BNP) was taken to determine the stability of HF.
The Minnesota Living with Heart Failure Questionnaire
[25], modified Medical Research Council dyspnoea scale
[26], and 10-point Borg score [27] were used to evaluate
quality of life, effect of breathlessness on daily activities,
and dyspnoea at rest, respectively. Additional data were
collected from medical records and personal interviews.
Arterial blood gas analysis was carried out in patients
with severe airway obstruction to determine whether
they had chronic respiratory failure [18].
Patients with newly diagnosed COPD were followed
up three months after standard treatment for COPD
with once-daily 18 μg tiotropium. A third blood sample
(NT-pro-BNP) was taken and spirometry was repeated
to confirm persistent airway obstruction characteristic of
COPD and exclude asthma as much as possible. Thus
only patients with persistent airway obstruction on three
months of follow-up were classified as having COPD.
Spirometry testing
Spirometry (MasterLab Pro; Jaeger; Würzburg, Germany)
was performed by trained and certified operators using
standard techniques and according to European Respira-
tory Society standards for acceptability and reproducibility
[28]. The reference values of the European Community
for Coal and Steel were used [28]. Subjects with airway
obstruction underwent post-bronchodilator spirometry
30 minutes after inhalation of four doses of 100 μg aero-
solised salbutamol and four doses of 20 μg aerosolised
ipratropium via Volumatic spacer. Participants were
instructed not to take bronchodilators 6–24 hours before
the tests, depending on the type of bronchodilator used.
At follow-up, salbutamol and ipratropium were used, as
previously described, when patients discontinued the use
of tiotropium > 24 hours prior to spirometry. Care was
taken to match the timing of the second spirometry test-
ing to the first to reduce variations that may occur over a
24-hour period.
Definitions
COPD was defined according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines as
post-bronchodilator ratio of forced expiratory volume in
one second to forced vital capacity (FEV1/FVC) < 0.7 [18].
COPD severity staging was determined on the basis of FEV1
percent predicted according to GOLD criteria: FEV1 ≥ 80%
predicted (stage I, mild), 50% ≤ FEV1 < 80% predicted (stage
II, moderate), 30% ≤ FEV1 < 50% predicted (stage III,
severe), and FEV1 < 30% predicted or FEV1 < 50% predicted
plus chronic respiratory failure (stage IV, very severe) [18].
Smoking status was defined as never (<100 cigarettes in
a lifetime), former (≥3 months ago), or current smoker
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the tobacco cigarette history and one PY was defined as
smoking 20 cigarettes a day for 1 year.
Dyspnoea was defined as resting dyspnoea or dyspnoea
at any level of exertion, chronic cough as cough ≥ 3 months
prior to the study, chronic sputum production as regular
production of sputum for ≥ 3 months in 2 consecutive
years, and aspecific bronchial hyperreactivity (ABHR) as
respiratory symptoms in response to perfumes, scent of
baking or paint, fog, cold air, or temperature changes.Ethical considerations
The study was approved by the regional Research
Ethics Committee Arnhem-Nijmegen in The Netherlands
(2009/101, NL27798.091.09, ClinicalTrials.gov Identifier
NCT01429376) and complies with the Declaration of
Helsinki. All participants gave written informed consent.Statistical analysis
Descriptive data are presented as mean ± standard devi-
ation (SD) or as number (%). Baseline characteristics of pa-
tients with and without COPD were compared using the
independent t-test or Mann–Whitney U test for continu-
ous variables and the chi-square or Fisher’s exact test for
categorical variables, as appropriate. Correlations between
COPD and LVEF and between COPD and NT-pro-BNP






Figure 1 Flow-diagram of screening and final inclusion of study parti
fraction; LVSD, left ventricular systolic dysfunction; PFTs, pulmonary functioncorrelation coefficient tests, respectively. Association be-
tween COPD and NYHA class was examined using the
chi-square test. Statistical analyses were performed using
the Statistical Package for Social Science (SPSS, version
15.0). All statistical tests were two-sided and a p-value
< 0.05 was considered significant.Results
Patient characteristics
After screening of the entire HF population, a cohort of
337 patients with CHF was initially enrolled in this
study. Thirty-eight patients withdrew informed consent
and 65 patients were excluded due to several other rea-
sons as specified in Figure 1. The remaining 234 patients
were finally included of whom 187 had stable CHF with-
out signs of pulmonary congestion. The characteristics
of these patients are shown in Tables 1 and 2. Mean age
and LVEF were 69 ± 10 years and 29 ± 7%, respectively,
and 78% were men. The majority of patients (72%) had
NYHA class II, while only 16% and 12% had NYHA
class I and III/IV, respectively. Almost 60% had an
ischaemic aetiology of HF. Other causes of HF were
idiopathic (24%), hypertension (6%), valve disease (6%),
tachycardiomyopathy (3%), and other (2%). Most pa-
tients were former or current smokers (83%) and re-
ported symptoms of dyspnoea (82%). Other respiratory
symptoms were less common (cough 36%, sputum 23%,1131 Not meeting inclusion criteria
131   Met exclusion criteria
91 Not able to cooperate or 
undergo spirometry
36 Asthma bronchiale
3   Participation in another study
1   Malignancy with bad prognosis
311   Refused informed consent
37     Other hospital, no contact 
54     Deceased
38 Withdrew informed consent  
112    Excluded:           
- 47 Unstable and/or congested CHF
- 44 Improved LVEF
- 10 No reliable PFT
- 4   Asthma bronchiale
- 4   LVSD without CHF
- 2   Did not cooperate
- 1   Deceased
cipants. CHF, chronic heart failure; LVEF, left ventricular ejection
tests.
Table 1 Characteristics of patients with and without COPD based on spirometry
All (n = 187) No COPD (n = 127) COPD (n = 60) P-value
Age, years 69 ± 10 68 ± 11 70 ± 9 0.173
Male sex, n (%) 146 (78) 94 (74) 52 (87) 0.051
BMI, kg/m2 28 ± 5 29 ± 5 28 ± 5 0.064
LVEF, % 29 ± 7 29 ± 7 29 ± 7 0.401
NYHA class, %
NYHA I-II 164 (88) 114 (90) 50 (83) 0.211
NYHA III-IV 23 (12) 13 (10) 10 (17) 0.211
Ischaemic aetiology 110 (59) 71 (56) 39 (65) 0.238
Smoking history, n (%) 0.008
Non-smoker 32 (17) 29 (23) 3 (5)
Current smoker 23 (12) 13 (10) 10 (17)
Former smoker 132 (71) 85 (67) 47 (78)
PY, years 24 ± 24 21 ± 21 30 ± 28 0.016
Co-morbidity, n (%)
Myocardial infarction 109 (58) 71 (56) 38 (63) 0.336
Atrial fibrillation 54 (29) 38 (30) 16 (27) 0.647
Hypertension 80 (43) 51 (40) 29 (48) 0.291
Diabetes mellitus 46 (25) 33 (26) 13 (22) 0.522
PCI/CABG 76 (41) 48 (38) 28 (47) 0.249
CRT/ICD 64 (34) 49 (39) 15 (25) 0.068
Medication, n (%)
ACE-I/ARB 174 (93) 119 (94) 55 (92) 0.759
β-blockers 172 (92) 116 (91) 56 (93) 0.778
Selective 99 (58) 66 (57) 33 (59) 0.801
Non-selective 73 (42) 50 (43) 23 (41) 0.801
Diuretics 159 (85) 107 (84) 52 (87) 0.666
Aldosterone-antagonists 65 (35) 47 (37) 18 (30) 0.348
ICS/OCS 26 (14) 9 (7) 17 (28) 0.000
β-agonists 29 (16) 7 (6) 22 (37) 0.000
Anticholinergics 29 (16) 6 (5) 23 (38) 0.000
Data are presented as mean ± SD and number (%).
Abbreviations: ACE-I/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, BMI body mass index, COPD chronic obstructive pulmonary
disease, CRT/ICD cardiac resynchronisation therapy/implantable cardioverter defibrillator, ICS/OCS inhalation/oral corticosteroids, LVEF left ventricular ejection
fraction, NYHA New York Heart Association, PCI/CABG percutaneous coronary intervention/coronary artery bypass grafting, PY pack-years.
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ally tailored drug treatment as maintenance therapy for
their CHF.
COPD prevalence
Initially, 61 (32.6%) CHF patients were diagnosed with
COPD based on spirometry of whom 34 had a history of
obstructive lung disease (OLD). Subsequently, 27 patients
with newly diagnosed COPD were followed up three
months after standard treatment for COPD. Two patients
were lost to follow-up; one deceased and the other with-
drew informed consent. One of the remaining 25 patients
no longer had airway obstruction at follow-up, which wasclassified as mild upon initial assessment. Thus, COPD
prevalence was 32.1% [25.4-38.8%] after three months of
follow-up.
COPD prevalence tended to be higher in men than
women (p = 0.051). It was also higher in former (36%)
and current smokers (43%) than in non-smokers (9%),
with no significant differences between current and
former smokers (Figure 2A). None of the 9 patients aged
between 31 and 50 years were diagnosed with COPD.
COPD prevalence according to other age categories is
shown in Figure 2B. Most patients had mild (46.7%) or
moderate (40.0%) COPD, while only 8.3% and 5.0% had
severe or very severe COPD, respectively.
Table 2 Pulmonary symptoms and results of questionnaires, laboratory tests, and spirometry of patients with and
without COPD based on spirometry
All (n = 187) No COPD (n = 127) COPD (n = 60) P-value
Symptoms, n (%)
Cough 67 (36) 38 (30) 29 (48) 0.014
Sputum 43 (23) 26 (20) 17 (28) 0.233
Dyspnoea 153 (82) 101 (80) 52 (87) 0.237
ABHR 55 (29) 29 (23) 26 (43) 0.004
Questionnaires
MLHFQ 20 ± 17 19 ± 17 21 ± 18 0.568
MRC 1.5 ± 1.3 1.4 ± 1.3 1.7 ± 1.4 0.149
Borg 0.9 ± 1.2 0.8 ± 1.2 1.1 ± 1.3 0.036
Laboratory data
NT-pro-BNP1, pmol/L 201 ± 289 184 ± 273 236 ± 321 0.290
NT-pro-BNP2, pmol/L 198 ± 308 179 ± 289 239 ± 345 0.250
Spirometry
FEV1, L 2.5 ± 0.8 2.7 ± 0.8 2.1 ± 0.7 0.000
FEV1, % predicted 88 ± 21 96 ± 15 72 ± 22 0.000
FVC, L 3.7 ± 1.0 3.7 ± 1.0 3.8 ± 1.0 0.699
FVC, % predicted 102 ± 19 102 ± 17 101 ± 23 0.602
FEV1/FVC, % 68 ± 11 74 ± 5 55 ± 10 0.000
Data are presented as mean ± SD. Only pre-bronchodilator lung function test results are presented to make comparison between groups possible. Laboratory data
1 and 2 refer to first (at baseline) and second (one month later) blood samples, respectively.
Abbreviations: ABHR aspecific bronchial hyperreactivity, COPD chronic obstructive pulmonary disease, FEV1/FVC ratio of forced expiratory volume in one second to
forced vital capacity, MLHFQ Minnesota Living with Heart Failure Questionnaire, MRC modified Medical Research Council dyspnoea scale, NT-pro-BNP N-terminal
pro-B natriuretic peptide.
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COPD was both over- and underdiagnosed (Figure 2 and
Table 3). In terms of overdiagnosis, 32% (16/50) of pa-
tients with a history of OLD failed to demonstrate airway
obstruction. In terms of underdiagnosis, 19% (26/137) of
patients without a history of OLD were newly diagnosed
with COPD based on spirometry. A history of OLD was
defined as COPD (n = 43) or not further specified airway
obstruction (n = 7) based on patient charts and/or general
practitioner diagnosis.
Determinants of COPD
Table 1 shows characteristics of patients with and without
COPD based on spirometry. Pulmonary symptoms and the
results of questionnaires, laboratory tests, and spirometry
are presented in Table 2. In univariate analysis patients with
COPD were generally men who smoked more, used more
pulmonary medication, had more respiratory symptoms of
cough, ABHR, and dyspnoea according to Borg score, and
tended to have a lower body mass index. In addition, they
had worse lung function test results except for FVC. Other
variables studied did not significantly vary between patients
with and without COPD based on spirometry.
COPD was not associated with a higher NYHA class
(p = 0.130). Also, there were no significant correlationsbetween COPD and LVEF (p = 0.401) or NT-pro-BNP
(p = 0.251).
Discussion
We observed a high prevalence (32.1%) of COPD in a
well defined subgroup of stable CHF patients without
pulmonary congestion who were recruited from two out-
patient cardiology departments of a large general hospital.
Using a three month follow-up spirometry to confirm ini-
tial diagnosis of de novo COPD did not change COPD
prevalence significantly. The majority of patients remained
obstructive at follow-up after three month of treatment
with tiotropium.
Contrary to our results, initial airway obstruction was
found in 19% of patients hospitalised for congestive sys-
tolic HF in the study of Brenner et al. [14], but had
resolved in 47% of these patients six months after dis-
charge. This indicates that airway obstruction is a dynamic
phenomenon in patients with HF, which often resolves
after re-compensation. Therefore, a careful timing and in-
terpretation of PFTs is required to avoid misdiagnosis and
inappropriate treatment [2]. Ideally, lung function mea-
surements should be obtained under stable conditions
when clinically euvolemic to establish a valid diagnosis of

















































No history of OLD
Figure 2 COPD prevalence and underdiagnosis according to (A)
gender and smoking status, and (B) age categories. COPD,
chronic obstructive pulmonary disease; CS, current smokers; FS,
former smokers; NS, non-smokers; OLD, obstructive lung disease. The
grey parts of the bar represent the proportion of patients with COPD
based on spirometry who did not have a history of OLD (i.e. previously
underdiagnosed patients).
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were reproducibly obstructed at follow-up in the current
study. There was no indication of asthma in the patient
who was not reproducibly obstructed at follow-up.
Our results support previous findings that COPD fre-
quently coexists with HF [15-17,20-22], but are in con-
trast to the study of Brenner et al. [14] who found only
9% of patients with systolic HF to have concomitantTable 3 Underdiagnosis and overdiagnosis of COPD
COPD (+) COPD (−) Total
History of OLD (+) 34 (18.2) 16 (8.6) 50 (26.7)
History of OLD (−) 26 (13.9) 111 (59.4) 137 (73.3)
Total 60 (32.1) 127 (67.9) 187 (100)
Data are presented as number (%).
Abbreviations: COPD chronic obstructive pulmonary disease, OLD obstructive
lung disease.COPD, probably explained by the high number of never
smokers (45.6%) included in their study. Several factors
might explain the high coexistence of these two diseases,
including sharing of environmental (mainly smoking) or
genetic risk factors, advanced age, systemic inflammation,
and a relationship between a reduction in pulmonary and
heart function [2,5-7,29-33]. Also, COPD patients are at an
increased risk of co-morbidities such as type 2 diabetes,
which in turn are an important risk for cardiovascular dis-
ease [30]. Furthermore, factors that increase stress on the
cardiovascular system or precipitate arrhythmic events can
also explain the association between COPD and cardiovas-
cular disease, including hypoxemia, hyperinflation, hyper-
ventilation, neurohumoral disturbances, increased work of
breathing and oxygen consumption, pulmonary hyperten-
sion, and the use of pulmonary medication [29,30,32,34].
Finally, other factors, such as oxidative stress, endothelial
dysfunction, arterial stiffness, and connective tissue degrad-
ation have also been suggested to play a role [32,34].
Since spirometry is still underutilized even in a tertiary-
care facility [19], it seems reasonable to consider routine
spirometry testing in patients with CHF to diagnose or rule
out COPD, a co-morbidity with important therapeutic and
prognostic implications [2,10-16,22] which is still greatly
under- and overdiagnosed as found in this study (19% and
32%, respectively). Indeed, diagnostic difficulties have been
stressed before, including the overlap in signs, symptoms,
and risk factors, the underuse of spirometry despite the fact
that objective evidence of airway obstruction is mandatory
for diagnosing COPD, and difficulties with interpreting
spirometry results, especially in patients with decompen-
sated HF [2,4-7,14]. This raises concerns regarding possible
inappropriate treatment of COPD in an already vulnerable
group of patients and as a result possible adverse impact on
health and outcome.
Unfortunately, the current study was not large enough
to find predictors of newly diagnosed COPD to make
specific recommendations regarding which subgroup of
patients should be tested. Also, it should be noted that a
large proportion (69,2%) of newly diagnosed COPD pa-
tients had only mild airway obstruction that may repre-
sent a physiological decline of lung function with age
instead of a disease [35,36]. It is unknown whether an
additional diagnosis and treatment of COPD in these pa-
tients would improve health outcomes and change their
prognosis. This warrants further research to establish
the effectiveness of screening of patients with CHF for
COPD in terms of symptomatic relief and improvement
of the outcome as well as cost-effectiveness of such a
policy. Until then, spirometry could be used in CHF pa-
tients with pulmonary symptoms despite an adequate
treatment for their HF, especially in the presence of risk
factors for COPD, such as a smoking history of ≥ 10 PY
and occupational exposures. Importantly, spirometry
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misdiagnosis and inappropriate treatment of COPD [2].
The current study has some limitations that deserve fur-
ther discussion. It is important to realise that the results
may not be applicable to all patients with CHF, since we
did not include patients with preserved systolic function.
The diagnosis of HF with preserved systolic function is
challenging and particularly difficult to establish in pa-
tients with COPD [5]. Thus, to avoid possible overesti-
mation of COPD prevalence in our population, we only
included patients with LVSD. Also, patients with more
severe HF could have been under-represented in this
study because of inability to participate. COPD prevalence
may therefore have been somewhat underestimated. Like-
wise, there may be a recruitment bias in the cohort, given
the refusal of 311 patients to provide informed consent.
Finally, another limitation is the relatively small number
of patients, particularly with COPD. However, included
patient numbers are comparable to other recently pub-
lished studies [16,20-22].
Despite these limitations, our findings have potential
clinical implications. Our results indicate that confirma-
tory spirometry does not change a newly established diag-
nosis of COPD in the vast majority of patients with CHF,
provided that PFTs are obtained during stable and non-
congested conditions. The results also highlight the need
for extensive use of spirometry to decrease the burden of
undiagnosed or overdiagnosed COPD in patients with
CHF. Evidently, the frequent underdiagnosis and overdi-
agnosis of COPD is not only a concern in the general
population, but also in patients who are regularly moni-
tored in outpatient cardiology clinics. Physicians should
bear in mind that both diseases often coexist with import-
ant diagnostic and therapeutic difficulties and prognostic
implications. Thus, both conditions must be simultan-
eously assessed and collaboration between cardiologists
and pulmonologists is essential.
Conclusions
In conclusion, COPD is a frequent co-morbidity in pa-
tients with stable CHF without pulmonary congestion,
but is often unrecognized or overdiagnosed. To avoid
this and thus ensure adequate treatment of COPD in
CHF, PFTs should be routinely obtained in a stable and
non-congested condition. Under these conditions a con-
firmatory spirometry is unnecessary, as it does not
change a newly established diagnosis of COPD in the
vast majority of patients with CHF.
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